In:
Acta Haematologica, S. Karger AG, Vol. 129, No. 4 ( 2013), p. 197-206
Abstract:
〈 b 〉 〈 i 〉 Background and Aims: 〈 /i 〉 〈 /b 〉 Immunomodulatory properties of mesenchymal stem cells (MSCs) have been applied to reduce the incidence of graft-versus-host disease (GVHD) after hematopoietic stem cell transplantation (HSCT). Among the various sources of MSCs that have immunomodulatory effects in vitro, only placenta-derived MSCs (PD-MSCs) have not been evaluated in an in vivo model of GVHD. In this study, we investigated the immunomodulatory properties of PD-MSCs in vitro and evaluated their clinical potential for controlling GVHD in an animal model. 〈 b 〉 〈 i 〉 Methods: 〈 /i 〉 〈 /b 〉 A GVHD animal model was established by transplanting C57BL/6 donor bone marrow cells and spleen cells into lethally irradiated BALB/c recipient mice. To control GVHD, human PD-MSCs were transplanted into recipient mice (5 × 10 〈 sup 〉 5 〈 /sup 〉 or 1 × 10 〈 sup 〉 6 〈 /sup 〉 cells). 〈 b 〉 〈 i 〉 Results: 〈 /i 〉 〈 /b 〉 PD-MSCs suppressed mitogen-stimulated T cell proliferation in vitro in a dose-dependent manner. Moreover, PD-MSCs inhibited cytokine secretion (interleukin-12, tumor necrosis factor-α and interferon- & #947;) of activated T cells. In vivo, the survival rate in the PD-MSC group (transplanted with 1 × 10 〈 sup 〉 6 〈 /sup 〉 cells) was higher than that in the control group and histological scores were low in the PD-MSC group. 〈 b 〉 〈 i 〉 Conclusion: 〈 /i 〉 〈 /b 〉 We present the first evidence that human PD-MSCs can efficiently control GVHD in an HSCT in vivo model.
Type of Medium:
Online Resource
ISSN:
0001-5792
,
1421-9662
Language:
English
Publisher:
S. Karger AG
Publication Date:
2013
detail.hit.zdb_id:
1481888-7
detail.hit.zdb_id:
80008-9
